CLINICAL_TRIALS
trial_result
· 2010-10-28
Clinical Trial Update: Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF [Phase 2]
Summary
Phase 2 trial evaluating safety and efficacy of ATG003 in age-related macular degeneration patients receiving anti-VEGF therapy has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: CoMentis | Conditions: Age-Related Macular Degeneration | Phase 2 | Status: COMPLETED